Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004

Last updated: July 2, 2018
Sponsor: Karolinska University Hospital
Overall Status: Completed

Phase

3

Condition

Histiocytoma

Red Blood Cell Disorders

Bone Marrow Disorder

Treatment

N/A

Clinical Study ID

NCT00426101
HLH-2004
  • Ages < 18
  • All Genders

Study Summary

Without therapy HLH is often fatal, and often rapidly fatal. The treatment protocol HLH-94 has improved survival markedly as compared to the survival earlier. We now aim to improve survival further.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients who fulfil the diagnostic criteria of HLH.

Exclusion

Exclusion Criteria:

  • Prior cytotoxic or cyclosporin treatment for HLH.

Study Design

Total Participants: 368
Study Start date:
January 01, 2004
Estimated Completion Date:
December 31, 2017

Study Description

The most dangerous period after HLH diagnosis is the first 2 months. In HLH-2004 we provide additional therapy during this period as compared to in HLH-94.

Connect with a study center

  • Childhood Cancer Research Unit, Karolinska Hospital

    Stockholm, S-171 76
    Sweden

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.